If the iPSCs you would like to access are currently listed as unavailable or
you would like information on local partners in USA, Australia, New Zealand or Japan who can support order and delivery,
please get in touch via
Contact@EBiSC.org.
UKKi006-A
D4-cB, M4C4, NP0053-5
iPSC line
Timepoint: 48 hours post-passage
Magnification: 4x
Magnification: 4x
Timepoint: 48 hours post-passage
Magnification: 10x
Magnification: 10x
Timepoint: Confluence
Magnification: 4x
Magnification: 4x
Timepoint: Confluence
Magnification: 10x
Magnification: 10x
A CLIP contains information about an iPSC line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the iPSC line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
iPSC Line |
|
| hPSCreg name | UKKi006-A |
| Alternative name(s) |
D4-cB, M4C4, NP0053-5
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
Provider |
|
| Depositor | Klinikum der Universität zu Köln (UKK) |
| Owner | Institute for Neurophysiology, Medical Faculty |
| Distributors |
EBiSC
Institute for Neurophysiology, Medical Faculty
Scottish Centre for Regenerative Medicine
|
| Derivation country | Germany |
External iPSC Databases |
|
| hPSCreg | UKKi006-A |
| BioSamples | SAMEA2825851 |
| Cellosaurus | CVCL_9S59 |
| Wikidata | Q54990421 |
General iPSC Information |
|
| Publications | |
| This EBiSC iPSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 60-64 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | No |
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA2825874 |
iPSC Derivation#
General |
|
| Source cell type |
A mesenchymal stem cell that is part of the bone marrow.
|
| Source cell origin |
The soft tissue that fills the cavities of bones.
Synonyms
|
| Source cell type (free text) | Bone marrow-derived mesenchymal stromal cells (MSCs) |
| Age of donor (at collection) | 60-64 |
| Collected in | 2010 |
| Passage number reprogrammed | P4 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector silencing | Retrovirally encoded reprogramming factors OSKM are not expressed in iPSCs as determined by RT-PCR |
| Files and images showing reprogramming vector expressed or silenced | |
| Vector map | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | human ESC morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions#
Latest released batch |
|
| Culture medium | Essential E8 |
| Passage method | EDTA |
| Surface coating | Vitronectin |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | No |
iPSC Characterisation#
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA 1-80 |
Yes |
|
||||
| TRA1-80 |
Yes |
|
Morphology pictures
brightfield image of NP0053-5 iPSC colonies, day 2 post-thaw; 10x objective
brightfield image of NP0053-5 iPSC colony, day 2 post-thaw; 32x objective
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
Deletion of the short arm and duplikation of the long arm of Chr20 were detected.
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (iPSC Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Methylation profiling
|